血管紧张素受体阻滞剂与β受体阻滞剂治疗马方综合征:系统评价与Meta分析
该系统评价与Meta分析纳入9项试验的14篇报告共1449例马方综合征患者,比较ARB相关方案与单用BB的疗效与安全性。结果显示ARB单药疗效不劣于BB单药,ARB+BB联合方案在主动脉根部扩张方面优于BB单药且无显著不良反应。
要点
- ARB相关方案与单用BB在主动脉根部扩张方面疗效相当(SMD=-0.16,95%CI[-0.33;0.01],P=0.06)。
- ARB+BB联合亚组较单用BB显著减缓主动脉根部扩张(SMD=-0.26,95%CI[-0.40;-0.11],P<0.01)。
- 两组在其他主动脉扩张指标及心血管事件(夹层、手术、死亡)方面无显著差异。
核心结论
- ARB单药治疗的临床疗效不劣于BB单药治疗。
- ARB+BB联合治疗显示出更优的治疗效果,且无显著不良反应。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Web of Science和Cochrane Library数据库至2021年3月,纳入关于ARB相关(包括ARB单药和ARB+BB)与单用BB治疗马方综合征患者疗效与安全性的随机对照试验。
- 共纳入9项试验的14篇报告,涉及1449例患者。
- 使用修订版偏倚风险评估工具进行质量评价,采用比值比(OR)和标准均数差(SMD)及95%置信区间(CI)估计合并效应量。
主要发现
- 在主动脉根部扩张方面,ARB相关方案与单用BB方案疗效相当(合并SMD=-0.16,95%CI[-0.33;0.01],P=0.06)。
- 在ARB+BB vs 单用BB亚组中,观察到显著差异(合并SMD=-0.26,95%CI[-0.40;-0.11],P<0.01)。
- 两组在其他主动脉扩张相关指标(主动脉根部Z评分、升主动脉、肺动脉、主动脉瓣环、窦管交界、主动脉弓、胸主动脉和腹主动脉直径变化)或心血管事件(主动脉夹层、主动脉手术和死亡)方面均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several RCTs have been conducted to assess the efficacy and safety of angiotensin receptor blocker (ARB) and beta-blocker (BB) therapy for Marfan syndrome (MFS), but the existing evidence is limited and conflicting. This study aimed to compare the efficacy and safety of different therapies. METHODS: The PubMed, Embase, Web of Science, and Cochrane Library databases were electronically searched up to March 2021 to retrieve randomized controlled trials regarding the efficacy and safety of ARB-related (including ARB-only and ARB+BB treatment) and BB-only treatment for treating patients with MFS. The revised risk-of-bias tool was used for quality assessment. The odds ratio (OR) and standard mean difference (SMD) with 95% confidence interval (CI) were used to estimate the pooled effect size. RESULTS: Fourteen reports of 9 trials involving 1,449 patients were included in the meta-analysis. Regarding aortic root dilation, the ARB-related regimen has efficacy comparable with that of the BB-only regimen in patients with MFS (pooled SMD = -0.16, 95% CI [-0.33; 0.01]; P = 0.06), while in the ARB+BB vs. BB-only subgroup, a significant difference was observed (pooled SMD = -0.26; 95% CI [-0.40; -0.11]; P < 0.01). In addition, there were no significant differences in other aortic dilation-related measures (aortic root Z scores, ascending aorta, pulmonary artery, aortic annulus, sinotubular junction, aortic arch, thoracic aorta, and abdominal aorta diameter change) or cardiovascular events (aortic dissection, aortic surgery, and death) between the 2 regimens. CONCLUSION: Our results showed that the clinical efficacy of ARB-only therapy is not inferior to that of BB-only therapy. Moreover, ARB+BB therapy showed superior therapeutic effects without significant adverse effects.
引用
- Wang Z, Deng X, Kang X, et al. Angiotensin Receptor Blockers vs. Beta-Blocker Therapy for Marfan Syndrome: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2022. PMID: 34998935. doi:10.1016/j.avsg.2021.12.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。